

CONTENTS

Preface

xvii

1 Introduction to Pharmacokinetics and Pharmacodynamics

1

- 1.1 Introduction: Drugs and Doses, 1
- 1.2 Introduction to Pharmacodynamics, 3
 - 1.2.1 Drug Effects at the Site of Action, 3
 - 1.2.2 Agonists, Antagonists, and Concentration–Response Relationships, 6
- 1.3 Introduction to Pharmacokinetics, 9
 - 1.3.1 Plasma Concentration of Drugs, 10
 - 1.3.2 Processes in Pharmacokinetics, 11
- 1.4 Dose–Response Relationships, 13
- 1.5 Therapeutic Range, 14
 - 1.5.1 Determination of the Therapeutic Range, 16
- 1.6 Summary, 18

2 Passage of Drugs Through Membranes

20

- 2.1 Introduction, 20
- 2.2 Structure and Properties of Membranes, 21
- 2.3 Passive Diffusion, 22
 - 2.3.1 Transcellular Passive Diffusion, 24
 - 2.3.2 Paracellular Passive Diffusion, 26
- 2.4 Carrier-Mediated Processes: Transport Proteins, 27
 - 2.4.1 Uptake Transporters: SLC Superfamily, 28
 - 2.4.2 Efflux Transporters: ABC Superfamily, 29
 - 2.4.3 Characteristics of Transporter Systems, 31

vii

- 2.4.4 Simulation Exercise, 32
- 2.4.5 Clinical Examples of Transporter Involvement in Drug Response, 33

3 Drug Administration, Absorption, and Bioavailability

36

- 3.1 Introduction: Local and Systemic Drug Administration, 37
- 3.2 Common Routes of Systemic Drug Administration, 37
 - 3.2.1 Intravascular Direct Systemic Administration, 37
 - 3.2.2 Extravascular Parenteral Routes, 38
 - 3.2.3 Other Extravascular Routes, 38
- 3.3 Overview of Oral Absorption, 40
- 3.4 Extent of Drug Absorption, 41
 - 3.4.1 Bioavailability Factor, 41
 - 3.4.2 Individual Bioavailability Factors, 42
- 3.5 Determinants of the Bioavailability Factor, 43
 - 3.5.1 Disintegration, 43
 - 3.5.2 Dissolution, 43
 - 3.5.3 Formulation Excipients, 43
 - 3.5.4 Adverse Events Within the Gastrointestinal Lumen, 44
 - 3.5.5 Transcellular Passive Diffusion, 46
 - 3.5.6 Paracellular Passive Diffusion, 47
 - 3.5.7 Uptake and Efflux Transporters, 47
 - 3.5.8 Presystemic Intestinal Metabolism or Extraction, 50
 - 3.5.9 Presystemic Hepatic Metabolism or Extraction, 52
- 3.6 Factors Controlling the Rate of Drug Absorption, 53
 - 3.6.1 Dissolution-Controlled Absorption, 54
 - 3.6.2 Membrane Penetration-Controlled Absorption, 55
 - 3.6.3 Overall Rate of Drug Absorption, 55
- 3.7 Biopharmaceutics Classification System, 55
- Problems, 56
- References, 57

4 Drug Distribution

60

- 4.1 Introduction, 61
- 4.2 Extent of Drug Distribution, 61
 - 4.2.1 Distribution Volumes, 62
 - 4.2.2 Tissue Binding and Plasma Protein Binding: Concentrating Effects, 64
 - 4.2.3 Assessment of the Extent of Drug Distribution: Apparent Volume of Distribution, 65
 - 4.2.4 Plasma Protein Binding, 72
- 4.3 Rate of Drug Distribution, 79
 - 4.3.1 Perfusion-Controlled Drug Distribution, 80
 - 4.3.2 Diffusion-Controlled Drug Distribution, 82
- 4.4 Distribution of Drugs to the Central Nervous System, 83
- Problems, 86
- References, 87

- 2.4.4 Simulation Exercise, 32
- 2.4.5 Clinical Examples of Transporter Involvement in Drug Response, 33

3 Drug Administration, Absorption, and Bioavailability

36

- 3.1 Introduction: Local and Systemic Drug Administration, 37
 - 3.2 Common Routes of Systemic Drug Administration, 37
 - 3.2.1 Intravascular Direct Systemic Administration, 37
 - 3.2.2 Extravascular Parenteral Routes, 38
 - 3.2.3 Other Extravascular Routes, 38
 - 3.3 Overview of Oral Absorption, 40
 - 3.4 Extent of Drug Absorption, 41
 - 3.4.1 Bioavailability Factor, 41
 - 3.4.2 Individual Bioavailability Factors, 42
 - 3.5 Determinants of the Bioavailability Factor, 43
 - 3.5.1 Disintegration, 43
 - 3.5.2 Dissolution, 43
 - 3.5.3 Formulation Excipients, 43
 - 3.5.4 Adverse Events Within the Gastrointestinal Lumen, 44
 - 3.5.5 Transcellular Passive Diffusion, 46
 - 3.5.6 Paracellular Passive Diffusion, 47
 - 3.5.7 Uptake and Efflux Transporters, 47
 - 3.5.8 Presystemic Intestinal Metabolism or Extraction, 50
 - 3.5.9 Presystemic Hepatic Metabolism or Extraction, 52
 - 3.6 Factors Controlling the Rate of Drug Absorption, 53
 - 3.6.1 Dissolution-Controlled Absorption, 54
 - 3.6.2 Membrane Penetration-Controlled Absorption, 55
 - 3.6.3 Overall Rate of Drug Absorption, 55
 - 3.7 Biopharmaceutics Classification System, 55
- Problems, 56
References, 57

4 Drug Distribution

60

- 4.1 Introduction, 61
 - 4.2 Extent of Drug Distribution, 61
 - 4.2.1 Distribution Volumes, 62
 - 4.2.2 Tissue Binding and Plasma Protein Binding: Concentrating Effects, 64
 - 4.2.3 Assessment of the Extent of Drug Distribution: Apparent Volume of Distribution, 65
 - 4.2.4 Plasma Protein Binding, 72
 - 4.3 Rate of Drug Distribution, 79
 - 4.3.1 Perfusion-Controlled Drug Distribution, 80
 - 4.3.2 Diffusion-Controlled Drug Distribution, 82
 - 4.4 Distribution of Drugs to the Central Nervous System, 83
- Problems, 86
References, 87

5 Drug Elimination and Clearance 88

- 5.1 Introduction, 89
 - 5.1.1 First-Order Elimination, 90
 - 5.1.2 Determinants of the Elimination Rate Constant and the Half-Life, 91
 - 5.2 Clearance, 91
 - 5.2.1 Definition and Determinants of Clearance, 91
 - 5.2.2 Total Clearance, Renal Clearance, and Hepatic Clearance, 94
 - 5.2.3 Relationships Among Clearance, Volume of Distribution, Elimination Rate Constant, and Half-Life, 95
 - 5.2.4 Primary and Secondary Parameters, 96
 - 5.3 Renal Clearance, 97
 - 5.3.1 Glomerular Filtration, 97
 - 5.3.2 Tubular Secretion, 98
 - 5.3.3 Tubular Reabsorption, 100
 - 5.3.4 Putting Meaning into the Value of Renal Clearance, 101
 - 5.4 Hepatic Clearance, 102
 - 5.4.1 Phase I and Phase II Metabolism, 103
 - 5.4.2 The Cytochrome P450 Enzyme System, 104
 - 5.4.3 Glucuronidation, 105
 - 5.4.4 Drug–Drug Interactions, 106
 - 5.4.5 Hepatic Drug Transporters, 107
 - 5.4.6 Kinetics of Drug Metabolism, 109
 - 5.4.7 Hepatic Clearance, 111
 - 5.5 Measurement of Clearances, 115
 - 5.5.1 Total Body Clearance, 115
 - 5.5.2 Renal Clearance, 117
 - 5.5.3 Fraction of the Drug Excreted Unchanged, 120
- Problems, 121
References, 124

6 Compartmental Models in Pharmacokinetics 126

- 6.1 Introduction, 127
- 6.2 Expressions for Component Parts of the Dose–Plasma Concentration Relationship, 127
 - 6.2.1 Effective Dose, 127
 - 6.2.2 Rate of Drug Absorption, 128
 - 6.2.3 Rate of Drug Elimination, 129
 - 6.2.4 Rate of Drug Distribution, 129
- 6.3 Putting Everything Together: Compartments and Models, 130
 - 6.3.1 One-Compartment Model, 130
 - 6.3.2 Two-Compartment Model, 131
 - 6.3.3 Three-Compartment Model, 131
- 6.4 Examples of Complete Compartment Models, 133
 - 6.4.1 Intravenous Bolus Injection in a One-Compartment Model with First-Order Elimination, 133

5 Drug Elimination and Clearance 88

- 5.1 Introduction, 89
 - 5.1.1 First-Order Elimination, 90
 - 5.1.2 Determinants of the Elimination Rate Constant and the Half-Life, 91
- 5.2 Clearance, 91
 - 5.2.1 Definition and Determinants of Clearance, 91
 - 5.2.2 Total Clearance, Renal Clearance, and Hepatic Clearance, 94
 - 5.2.3 Relationships Among Clearance, Volume of Distribution, Elimination Rate Constant, and Half-Life, 95
 - 5.2.4 Primary and Secondary Parameters, 96
- 5.3 Renal Clearance, 97
 - 5.3.1 Glomerular Filtration, 97
 - 5.3.2 Tubular Secretion, 98
 - 5.3.3 Tubular Reabsorption, 100
 - 5.3.4 Putting Meaning into the Value of Renal Clearance, 101
- 5.4 Hepatic Clearance, 102
 - 5.4.1 Phase I and Phase II Metabolism, 103
 - 5.4.2 The Cytochrome P450 Enzyme System, 104
 - 5.4.3 Glucuronidation, 105
 - 5.4.4 Drug–Drug Interactions, 106
 - 5.4.5 Hepatic Drug Transporters, 107
 - 5.4.6 Kinetics of Drug Metabolism, 109
 - 5.4.7 Hepatic Clearance, 111
- 5.5 Measurement of Clearances, 115
 - 5.5.1 Total Body Clearance, 115
 - 5.5.2 Renal Clearance, 117
 - 5.5.3 Fraction of the Drug Excreted Unchanged, 120
- Problems, 121
- References, 124

6 Compartmental Models in Pharmacokinetics 126

- 6.1 Introduction, 127
- 6.2 Expressions for Component Parts of the Dose–Plasma Concentration Relationship, 127
 - 6.2.1 Effective Dose, 127
 - 6.2.2 Rate of Drug Absorption, 128
 - 6.2.3 Rate of Drug Elimination, 129
 - 6.2.4 Rate of Drug Distribution, 129
- 6.3 Putting Everything Together: Compartments and Models, 130
 - 6.3.1 One-Compartment Model, 130
 - 6.3.2 Two-Compartment Model, 131
 - 6.3.3 Three-Compartment Model, 131
- 6.4 Examples of Complete Compartment Models, 133
 - 6.4.1 Intravenous Bolus Injection in a One-Compartment Model with First-Order Elimination, 133

6.4.2	Intravenous Bolus Injection in a Two-Compartment Model with First-Order Elimination, 134	
6.4.3	First-Order Absorption in a Two-Compartment Model with First-Order Elimination, 135	
6.5	Use of Compartmental Models to Study Metabolite Pharmacokinetics, 136	
6.6	Selecting and Applying Models, 137	
	Problems, 138	
	Recommended Reading, 138	
7	Pharmacokinetics of an Intravenous Bolus Injection in a One-Compartment Model	139
7.1	Introduction, 140	
7.2	One-Compartment Model, 140	
7.3	Pharmacokinetic Equations, 142	
7.3.1	Basic Equation, 142	
7.3.2	Half-Life, 143	
7.3.3	Time to Eliminate a Dose, 143	
7.4	Simulation Exercise, 144	
7.5	Application of the Model, 145	
7.5.1	Predicting Plasma Concentrations, 145	
7.5.2	Duration of Action, 146	
7.5.3	Value of a Dose to Give a Desired Initial Plasma Concentration, 147	
7.5.4	Intravenous Loading Dose, 147	
7.6	Determination of Pharmacokinetic Parameters Experimentally, 148	
7.6.1	Study Design for the Determination of Parameters, 149	
7.6.2	Pharmacokinetic Analysis, 149	
7.7	Pharmacokinetic Analysis in Clinical Practice, 153	
	Problems, 155	
	Recommended Reading, 157	
8	Pharmacokinetics of an Intravenous Bolus Injection in a Two-Compartment Model	158
8.1	Introduction, 159	
8.2	Tissue and Compartmental Distribution of a Drug, 159	
8.2.1	Drug Distribution to the Tissues, 159	
8.2.2	Compartmental Distribution of a Drug, 160	
8.3	Basic Equation, 162	
8.3.1	Distribution: A , α , and the Distribution $t_{1/2}$, 163	
8.3.2	Elimination: B , β , and the Beta $t_{1/2}$, 163	
8.4	Relationship Between Macro and Micro Rate Constants, 164	
8.5	Primary Pharmacokinetic Parameters, 165	
8.5.1	Clearance, 165	
8.5.2	Distribution Clearance, 166	
8.5.3	Volume of Distribution, 167	
8.6	Simulation Exercise, 170	

8.7	Determination of the Pharmacokinetic Parameters of the Two-Compartment Model, 173	
8.7.1	Determination of Intercepts and Macro Rate Constants, 173	
8.7.2	Determination of the Micro Rate Constants: k_{12} , k_{21} , and k_{10} , 175	
8.7.3	Determination of the Primary Pharmacokinetic Parameters, 175	
8.8	Clinical Application of the Two-Compartment Model, 176	
8.8.1	Measurement of the Elimination Half-Life in the Postdistribution Phase, 176	
8.8.2	Determination of the Loading Dose, 177	
8.8.3	Evaluation of a Dose: Monitoring Plasma Concentrations and Patient Response, 179	
	Problems, 180	
	Recommended Reading, 181	
9	Pharmacokinetics of Extravascular Drug Administration	182
9.1	Introduction, 183	
9.2	Model for First-Order Absorption in a One-Compartment Model, 184	
9.2.1	Model and Equations, 184	
9.2.2	Determination of the Model Parameters, 186	
9.2.3	Absorption Lag Time, 192	
9.2.4	Flip-Flop Model and Sustained-Release Preparations, 192	
9.2.5	Determinants of T_{\max} and C_{\max} , 194	
9.3	Bioavailability, 195	
9.3.1	Bioavailability Parameters, 195	
9.3.2	Absolute Bioavailability, 197	
9.3.3	Relative Bioavailability, 198	
9.3.4	Bioequivalence, 198	
9.3.5	Example Bioavailability Analysis, 198	
9.4	Simulation Exercise, 198	
	Problems, 199	
	Recommended Reading, 200	
10	Introduction to Noncompartmental Analysis	201
10.1	Introduction, 201	
10.2	Mean Residence Time, 202	
10.3	Determination of Other Important Pharmacokinetic Parameters, 205	
10.4	Different Routes of Administration, 207	
10.5	Application of Noncompartmental Analysis to Clinical Studies, 208	
	Problems, 210	
11	Pharmacokinetics of Intravenous Infusion in a One-Compartment Model	212
11.1	Introduction, 213	
11.2	Model and Equations, 214	
11.2.1	Basic Equation, 214	

11.2.2	Application of the Basic Equation, 216	
11.2.3	Simulation Exercise: Part 1, 216	
11.3	Steady-State Plasma Concentration, 217	
11.3.1	Equation for Steady-State Plasma Concentrations, 217	
11.3.2	Application of the Equation, 217	
11.3.3	Basic Formula Revisited, 218	
11.3.4	Factors Controlling Steady-State Plasma Concentration, 218	
11.3.5	Time to Steady State, 219	
11.3.6	Simulation Exercise: Part 2, 220	
11.4	Loading Dose, 221	
11.4.1	Loading-Dose Equation, 221	
11.4.2	Simulation Exercise: Part 3, 223	
11.5	Termination of Infusion, 223	
11.5.1	Equations for Termination Before and After Steady State, 223	
11.5.2	Simulation Exercise: Part 4, 224	
11.6	Individualization of Dosing Regimens, 224	
11.6.1	Initial Doses, 224	
11.6.2	Monitoring and Individualizing Therapy, 225	
	Problems, 227	
12	Multiple Intravenous Bolus Injections in the One-Compartment Model	230
12.1	Introduction, 231	
12.2	Terms and Symbols Used in Multiple-Dosing Equations, 232	
12.3	Monoexponential Decay During a Dosing Interval, 234	
12.3.1	Calculation of Dosing Interval to Give Specific Steady-State Peaks and Troughs, 235	
12.4	Basic Pharmacokinetic Equations for Multiple Doses, 236	
12.4.1	Principle of Superposition, 236	
12.4.2	Equations That Apply Before Steady State, 236	
12.5	Steady State, 238	
12.5.1	Steady-State Equations, 238	
12.5.2	Average Plasma Concentration at Steady State, 240	
12.5.3	Fluctuation, 242	
12.5.4	Accumulation, 243	
12.5.5	Time to Reach Steady State, 244	
12.5.6	Loading Dose, 245	
12.6	Basic Formula Revisited, 245	
12.7	Pharmacokinetic-Guided Dosing Regimen Design, 246	
12.7.1	General Considerations for Selection of the Dosing Interval, 246	
12.7.2	Protocols for Pharmacokinetic-Guided Dosing Regimens, 247	
12.8	Simulation Exercise, 251	
	Problems, 253	
	References, 253	

- 13 Multiple Intermittent Infusions 254**
- 13.1 Introduction, 254
 - 13.2 Steady-State Equations for Multiple Intermittent Infusions, 256
 - 13.3 Monoexponential Decay During a Dosing Interval: Determination of Peaks, Troughs, and Elimination Half-Life, 259
 - 13.3.1 Determination of Half-Life, 259
 - 13.3.2 Determination of Peaks and Troughs, 261
 - 13.4 Determination of the Volume of Distribution, 261
 - 13.5 Individualization of Dosing Regimens, 264
 - 13.6 Simulation Exercise, 265 Problems, 265
- 14 Multiple Oral Doses 267**
- 14.1 Introduction, 267
 - 14.2 Steady-State Equations, 268
 - 14.2.1 Time to Peak Steady-State Plasma Concentration, 269
 - 14.2.2 Maximum Steady-State Plasma Concentration, 270
 - 14.2.3 Minimum Steady-State Plasma Concentration, 271
 - 14.2.4 Average Steady-State Plasma Concentration, 271
 - 14.2.5 Overall Effect of Absorption Parameters on a Steady-State Dosing Interval, 272
 - 14.3 Equations Used Clinically to Individualize Oral Doses, 272
 - 14.3.1 Protocol to Select an Appropriate Equation, 273
 - 14.4 Simulation Exercise, 274
 - References, 265
- 15 Nonlinear Pharmacokinetics 277**
- 15.1 Linear Pharmacokinetics, 277
 - 15.2 Nonlinear Processes in Absorption, Distribution, Metabolism, and Elimination, 280
 - 15.3 Pharmacokinetics of Capacity-Limited Metabolism, 281
 - 15.3.1 Kinetics of Enzymatic Processes, 282
 - 15.3.2 Plasma Concentration–Time Profile, 283
 - 15.4 Phenytoin, 284
 - 15.4.1 Basic Equation for Steady State, 285
 - 15.4.2 Estimation of Doses and Plasma Concentrations, 287
 - 15.4.3 Influence of K_m and V_{max} and Factors That Affect These Parameters, 289
 - 15.4.4 Time to Eliminate the Drug, 290
 - 15.4.5 Time to Reach Steady State, 291
 - 15.4.6 Individualization of Doses of Phenytoin, 292
 - Problems, 295
 - References, 296

16 Introduction to Pharmacodynamic Models and Integrated Pharmacokinetic–Pharmacodynamic Models	297
16.1 Introduction, 298	
16.2 Classic Pharmacodynamic Models Based on Traditional Receptor Theory, 299	
16.2.1 Receptor Binding, 300	
16.2.2 Response–Concentration Models, 302	
16.3 Empirical Pharmacodynamic Models Used Clinically, 307	
16.3.1 Sigmoidal E_{\max} and E_{\max} Models, 308	
16.3.2 Linear Adaptations of the E_{\max} Model, 310	
16.4 Integrated PK–PD Models: E_{\max} Model Combined with a PK Model for Intravenous Bolus Injection in a One-Compartment Model, 312	
16.4.1 Simulation Exercise, 314	
16.5 Hysteresis and the Effect Compartment, 315	
16.5.1 Simulation Exercise, 318	
Problems, 319	
References, 321	
17 Mechanism-Based Integrated Pharmacokinetic–Pharmacodynamic Models	323
17.1 Introduction, 324	
17.2 Alternative Models for Drug–Receptor Interaction: Operational Model of Agonism, 325	
17.2.1 Simulation Exercise, 329	
17.3 Physiological Turnover Model and Its Characteristics, 329	
17.3.1 Points of Drug Action, 330	
17.3.2 System Recovery After Change in Baseline Value, 330	
17.4 Indirect Effect Models, 331	
17.4.1 Characteristics of Indirect Effect Drug Responses, 333	
17.4.2 Characteristics of Indirect Effect Models Illustrated Using Model I, 334	
17.4.3 Other Indirect Models, 340	
17.5 Transduction and Transit Compartment Models, 340	
17.5.1 Simulation Exercise, 343	
17.6 Tolerance Models, 344	
17.6.1 Counter-regulatory Force Model, 345	
17.6.2 Precursor Pool Model of Tolerance, 348	
17.7 Irreversible Drug Effects, 350	
17.7.1 Application of the Turnover Model to Irreversible Drug Action, 350	
17.7.2 Model for Hematological Toxicity of Anticancer Drugs, 352	
17.8 Disease Progression Models, 356	
17.8.1 Generation of Drug Response, 356	
17.8.2 Drug Interaction with a Disease, 356	
17.8.3 Disease Progression Models, 356	
Problems, 360	
References, 365	

Appendix A Review of Exponents and Logarithms 368

- A.1 Exponents, 368
- A.2 Logarithms: log and ln, 369
- A.3 Performing Calculations in the Logarithmic Domain, 370
 - A.3.1 Multiplication, 370
 - A.3.2 Division, 371
 - A.3.3 Reciprocals, 371
 - A.3.4 Exponents, 371
- A.4 Calculations Using Exponential Expressions and Logarithms, 371
- A.5 Decay Function: e^{-kt} , 373
- A.6 Growth Function: $1 - e^{-kt}$, 374
- A.7 Decay Function in Pharmacokinetics, 374
- Problems, 375

Appendix B Rates of Processes 377

- B.1 Introduction, 377
- B.2 Order of a Rate Process, 378
- B.3 Zero-Order Processes, 378
 - B.3.1 Equation for Zero-Order Filling, 378
 - B.3.2 Equation for Zero-Order Emptying, 379
 - B.3.3 Time for Zero-Order Emptying to Go to 50% Completion, 379
- B.4 First-Order Processes, 380
 - B.4.1 Equation for a First-Order Process, 380
 - B.4.2 Time for 50% Completion: The Half-Life, 381
- B.5 Comparison of Zero- and First-Order Processes, 382
- B.6 Detailed Example of First-Order Decay in Pharmacokinetics, 382
 - B.6.1 Equations and Semilogarithmic Plots, 382
 - B.6.2 Half-Life, 383
 - B.6.3 Fraction or Percent Completion of a First-Order Process Using First-Order Elimination as an Example, 384
- B.7 Examples of the Application of First-Order Kinetics to Pharmacokinetics, 385

Appendix C Creation of Excel Worksheets for Pharmacokinetic Analysis 387

- C.1 Measurement of AUC and Clearance, 387
 - C.1.1 Trapezoidal Rule, 388
 - C.1.2 Excel Spreadsheet to Determine $AUC_{0 \rightarrow \infty}$ and Clearance, 389
- C.2 Analysis of Data from an Intravenous Bolus Injection in a One-Compartment Model, 393
- C.3 Analysis of Data from an Intravenous Bolus Injection in a Two-Compartment Model, 394
- C.4 Analysis of Oral Data in a One-Compartment Model, 398
- C.5 Noncompartmental Analysis of Oral Data, 399

Appendix D Derivation of Equations for Multiple Intravenous Bolus Injections 403

- D.1 Assumptions, 403

D.2	Basic Equation for Plasma Concentration After Multiple Intravenous Bolus Injections, 403	
D.3	Steady-State Equations, 406	
Appendix E	Summary of the Properties of the Fictitious Drugs Used in the Text	407
Appendix F	Computer Simulation Models	409
	Glossary of Abbreviations and Symbols	410
	Index	415